

Hypereosinophilic syndrome in an infant

Rodrigo Hernández-Benítez*, Juan Vicencio-Rivas, José Iglesias-Leboreiro, Mónica Martina-Luna, M. Raquel Madrazo-Miranda and Sofía Lases-Rufeil

Departamento de Pediatría, Hospital Español de México, Mexico City, Mexico

Abstract

Background: The hypereosinophilic syndrome (HES) is defined by an eosinophilic count $> 1500 \text{ cells/mm}^3$ and organ damage or dysfunction that can be easily mistaken for atopic dermatitis or pulmonary pathologies. Timely diagnosis and treatment can improve the prognosis and avoid heart and renal complications or lung fibrosis. **Case report:** The case of an infant is reported with a 24-h evolution of cough and fever, personal history of atopic dermatitis, and a generalized dermatosis 2 months earlier. In the initial approach, respiratory disease was considered. However, blood count reported hypereosinophilia, which led to further studies and the diagnosis of the HES. **Conclusions:** Although a rare pathology, it is important to consider the HES in children with common symptoms, and unusual evolution or poor treatment response and persistent hypereosinophilia.

Key words: Hypereosinophilic syndrome. Atopic dermatitis. Infant.

Síndrome hipereosinofílico en un lactante

Resumen

Introducción: El síndrome hipereosinofílico se define por la cuenta de eosinófilos $> 1,500 \text{ células/mm}^3$ con daño orgánico o disfunción, sin ninguna causa subyacente. Puede ser fácilmente confundido con una dermatitis atópica o con patologías pulmonares. El diagnóstico temprano y el tratamiento adecuado pueden mejorar el pronóstico y evitar complicaciones cardíacas y renales o el desarrollo de fibrosis pulmonar. **Caso clínico:** Se reporta el caso de un lactante con tos y fiebre de 24 horas de evolución y una historia personal de dermatitis atópica, además de dermatosis generalizada dos meses antes. Inicialmente, se consideró como una enfermedad respiratoria; sin embargo, la cuenta de células sanguíneas reportó hipereosinofilia, lo cual condujo a estudios confirmatorios y al diagnóstico de síndrome hipereosinofílico. **Conclusiones:** A pesar de ser una enfermedad rara, es de suma importancia considerar el síndrome hipereosinofílico en el diagnóstico diferencial en niños con una evolución atípica o con pobre respuesta al tratamiento, además de hipereosinofilia persistente.

Palabras clave: Síndrome hipereosinofílico. Dermatitis atópica. Lactante.

Correspondence:

*Rodrigo Hernández-Benítez
E-mail: roy210983@gmail.com

Date of reception: 30-12-2018
Date of acceptance: 20-02-2019
DOI: 10.24875/BMHIM.M19000037

Available online: 13-05-2019
Bol Med Hosp Infant Mex. 2019;76:134-137
www.bmhim.com

1665-1146/© 2019. Hospital Infantil de México Federico Gómez, published by Permanyer México SA de CV, all rights reserved.

Introduction

The hypereosinophilic syndrome (HES) is defined by the presence of an eosinophilic count $> 1500 \text{ cell/mm}^3$ with organ damage or dysfunction without any underlying cause, which can be easily mistaken for atopic dermatitis or pulmonary pathologies. Early diagnosis and treatment can improve the prognosis and avoid heart and renal complications or lung fibrosis¹.

Case report

A male infant of 1 year and 5 months of age was admitted to the emergency room with a 7-day history of fever, pharyngitis, and generalized dermatosis that affected palms and soles of the feet with no prior medication (Fig. 1). With a complete immunization schedule, a personal history of atopic dermatitis for 1 year of age with inadequate response to conventional treatment was registered.

Complete blood count (CBC) showed $18,900 \text{ mm}^3$ leukocytes, 36% neutrophils, 12% lymphocytes, 17% eosinophils (3213 cell/mm^3), and 23% immature neutrophils. The hypereosinophilia was attributed to the severe atopic dermatitis, for which a course of antibiotics for supposed erysipelas was started. No response to treatment was observed after 3 days. Subsequently, the infant was diagnosed with incomplete Kawasaki disease and received a single dose of gamma globulin and daily steroids. He was discharged 7 days later with a satisfactory evolution.

Two months after, the patient was readmitted with a 24-h history of emetic cough and fever. No history of premedication or use of antibiotics or nonsteroidal anti-inflammatory drugs was registered. Signs were as follows: blood pressure 106/64 mmHg, heart rate 144/min, respiratory rate 32/min, oxygen saturation 92%, temperature 37.8°C , capillary refill time of 2 s, weight 10.8 kg, and height 81 cm. The physical examination revealed bilateral anterior and posterior cervical, occipital, inguinal, and axillary lymphadenopathies no larger than 1 cm of soft consistency. Furthermore, the patient showed respiratory distress, polypnea, and hypoventilation in both pulmonary bases and transmitted rales. No heart murmur or visceromegaly was observed.

Initially, the patient was treated for an airway infection, managing respiratory distress with salbutamol and ipratropium bromide. Due to the lymphadenopathies and fever, a chest X-ray was performed, which revealed pulmonary hyperinflation (Fig. 2).



Figure 1. Generalized dermatosis affecting palms and soles of the feet.




Figure 2. Chest X-ray with pulmonary hyperinflation.



Figure 3. Peripheral blood smear with a high number of eosinophils and preserved morphology.

CBC showed $43,900 \text{ mm}^3$ leukocytes, 12.7% neutrophils, 11.7% lymphocytes, 2.4% monocytes, 68.8% eosinophils ($30,203 \text{ mm}^3$), 2% immature neutrophils, 13.4 g/dl hemoglobin, 37.5% hematocrit, and 215,000 platelets (Fig. 3).




Figure 4. Hypocellular bone marrow with significant eosinophilia of the granulocytic series, moderate erythroid hypoplasia, and megakaryocytic hyperplasia.

To confirm HES diagnosis, additional tests were performed with the following results: immunoglobulins [IgA, 66.5 mg/dl (reference range (rr) 70-400 mg/dl); IgG, 1930 mg/dl (rr 700-1600 mg/dl); IgE, 1598.9 mg/dl (rr 0-100 mg/dl); IgM, 133 mg/dl (rr 40-230 mg/dl)], complements: C3, 104 mg/dl (rr 100-180 mg/dl) and C4, 19.7 mg/dl (rr 16-40 mg/dl), vitamin B12, 1078 pg/ml (rr 200-1000 pg/ml), and tryptase, < 0.2 U/l (rr < 2 U/l). The coproparasitoscopic results were negative, and both renal and liver functions were normal, as well as serum electrolytes.

Bone marrow biopsy showed 70% cellularity, significant eosinophilia of the granulocytic series, moderate erythroid hypoplasia, and megakaryocytic hyperplasia. Almost 80% of the granulocytic series corresponded to eosinophils; however, it was reported negative to any neoplastic process. As no CD34, CD117, or blasts were observed, a neoplastic process was discarded (Fig. 4).

The sequence 4Q12 (FIP1L1-PDGFA) was negative, as well as antinuclear antibodies (< 1:40).

Flow cytometry analysis showed the following values: CD3, 1418 cells/ μ l (rr 600-5000 cells/ μ l); CD4, 948.1 cells/ μ l (rr 400-3500 cells/ μ l); CD8, 344 cells/ μ l (rr 200-1900 cells/ μ l); CD56, 60 cells/ μ l; and CD19, 1468 cells/ μ l. No cardiac abnormalities, such as valves regurgitation, infiltrates, or intracardiac thrombus, were observed. Chest computed tomography scan revealed diffuse bilateral alveolitis (Fig. 5).

After analyzing blood tests, the hematologist confirmed the HES diagnosis. Treatment was started with intravenous prednisone 1 mg/kg per dose every 24 h in addition to inhaled budesonide. The infant responded favorably to treatment and discharged 6 days later. CBC before discharge showed 10,000 leukocytes with 6% eosinophils (600 cells). Steroid treatment continued at home, until clinical and laboratory remission.




Figure 5. Diffuse bilateral alveolitis in chest computed tomography scan.

Discussion

HES is a rare myeloproliferative disorder with hypereosinophilia (> 1500 cells/mm³) in the absence of another disease (such as allergies or infections) and with evidence of dysfunction at least in one organ¹.

Chronic hypereosinophilia can lead to symptoms secondary to enzyme production by eosinophils or due to tissue infiltration. Different mechanisms can generate eosinophil overproduction, such as a stem cell mutation, which leads to the expression of a fused gene containing platelet-derived growth factor receptor (PDGF-R), alpha polypeptide platelet-derived growth factor receptor alpha (PDGFRA) with tyrosine kinase activity (FIP1L1-PDGFA gene fusion), or interleukin-5 (IL-5) overproduction due to Th2 cell activity, with unusual phenotype or reordering clonal patterns of genes with Th2 cell receptors².

The HES mainly affects adults between 20 and 50 years of age, with a 9:1 male-female ratio. The first case reported was a 30-year-old male with hypereosinophilia, high levels of IgE and IgM, and skin, and pulmonary and vascular affection. A national multicentric French study reported 21 cases, including a 5-year-old patient, being skin affection the most common initial symptom³⁻⁸.

This case report is significant because the patient fulfilled all the main criteria of HES, which is very rare in children, as no population-based registries are available. Although the actual incidence of HES is unknown, the review of literature for published *de novo* HES case reports using PubMed database from 1999 to June 2011 showed 141 cases (only 33 were children: 19 males and 14 females). The median age at diagnosis was 11 years

(range 38 weeks-16 years), with a wide variety of symptoms, which the skin, lungs, and heart were the most frequently reported⁹.

During the first year of life, the present case most likely started to express skin affection attributed to atopic dermatitis. Since the first visit to the ER, the eosinophilia was evident in the CBC but still considered as related to atopy and other more common diagnoses. It was until the second admission when a further study for HES was performed, following the criteria of a total eosinophil count >1500 cell/mm³ in at least two different occasions within 1 month.

The National Institute of Health reported a case series with HES, in which the most common symptoms were fatigue (26%), cough (24%), fever (12%), dermatosis (12%), and retinal lesions (10%)^{7,10}. Lefèvre et al. analyzed 21 patients with the lymphoid variant and reported skin lesions in 18 patients including angioedema, urticaria, pruritus, and maculopapular rash; lymphadenopathies in 13 patients; personal history of asthma in five patients; eczema in six patients; and pulmonary affection, such as bronchitis, asthma, eosinophilic alveolitis, dyspnea, and pleural effusion in four patients. Gastrointestinal, neurological, or cardiovascular symptoms were less frequent; only one patient showed splenomegaly⁵.

Radiographic findings in the lymphoid variant of HES include pleural effusion and diffuse or focal infiltrates, observed in the present case. In the pulmonary biopsy, eosinophils can be found. Furthermore, infiltrate improves with steroid therapy, though a risk of pulmonary fibrosis as a late complication exists¹¹. However, a lymphoid variant of HES (L-HES) was not concluded in this case because the diagnosis is based on detecting the most common aberrant phenotypes in L-HES (CD3-CD4+ and CD3+CD4-CD8-) by flow cytometry techniques^{5,12}. Unfortunately, this information was not available for the present report.

In the HES, steroid response is often favorable, as observed with the patient. The suggested treatment is prednisone 0.5-1 mg/kg per day, while the second-line drugs are alpha interferon, mepolizumab, and cyclosporine. A close follow-up of the patients by a pediatrician or hematologist is essential, due to the risk of T-cell lymphoma in further years. The development of late lymphadenopathies must be studied to rule out this disease. Patients that develop lymphoma usually fail to respond to conventional chemotherapy treatment^{5,12,13}.

This report allows to understanding HES in an infant whose symptoms may be present in other common pediatric illnesses such as atopic dermatitis, erysipelas, incomplete Kawasaki disease, or airway affections.

Although rare, this pathology should be considered in a patient with common symptoms, and unusual evolution or poor treatment response and persistent hypereosinophilia. A complete assessment is vital to discard other significant complications, including cytogenetic disorders, and to perform a close follow-up due to the risk of lymphoma.

Ethical disclosures

Protection of human and animal subjects. The authors declare that no experiments were performed on humans or animals for this study.

Confidentiality of data. The authors declare that they have followed the protocols of their work center on the publication of patient data.

Right to privacy and informed consent. The authors have obtained the written informed consent of the patients or subjects mentioned in the article. The corresponding author is in possession of this document.

Conflicts of interest

The authors declare no conflicts of interest.

References

1. Valent P, Klion AD, Horny HP, Roufosse F, Gotlib J, Weller PF, et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. *J Allergy Clin Immunol.* 2012;130:607-12.e9.
2. Cools J, De Angelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. *N Engl J Med.* 2003;348:1201-14.
3. Cogan E, Schandené L, Crusiaux A, Cochaux P, Velu T, Goldman M. Brief report: clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome. *N Engl J Med.* 1994;330:535-8.
4. Roufosse F, Cogan E, Goldman M. The hypereosinophilic syndrome revisited. *Annu Rev Med.* 2003;54:169-84.
5. Lefèvre G, Copin MC, Staumont-Sallé D, Avenel-Audran M, Aubert H, Taieb A, et al. The lymphoid variant of hypereosinophilic syndrome: a study of 21 patients with CD3-CD4+ aberrant T-cell phenotype. *Medicine (Baltimore).* 2014;93:255-66.
6. Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. *Blood.* 1994;83:2759-79.
7. Spry C. Eosinophils. A comprehensive review and guide to the scientific and medical literature. Oxford (UK): Oxford Medical Publications; 1988.
8. Fauci AS, Harley JB, Roberts WC, Ferrans VJ, Gralnick HR, Bjornson BH. NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. *Ann Intern Med.* 1982;97:78-92.
9. van Grotel M, de Hoog M, de Krijger RR, Beverloo HB, van den Heuvel-Eibrink MM. Hypereosinophilic syndrome in children. *Leuk Res.* 2012;36:1249-54.
10. Simon HU, Plotz SG, Dummer R, Blaser K. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. *N Engl J Med.* 1999;341:1112-20.
11. Wechsler ME. Pulmonary eosinophilic syndromes. *Immunol Allergy Clin North Am.* 2007;27:477-92.
12. Ogbogu PU, Bochner BS, Butterfield JH, Gleich GJ, Huss-Marp J, Kahn JE, et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and responses to therapy. *J Allergy Clin Immunol.* 2009;124:1319-25.
13. Roufosse F, de Lavarelle A, Schandené L, Cogan E, Georgelas A, Wagner L, et al. Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome. *J Allergy Clin Immunol.* 2010;126:828-35.